JP6169494B2 - インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法 - Google Patents

インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法 Download PDF

Info

Publication number
JP6169494B2
JP6169494B2 JP2013552568A JP2013552568A JP6169494B2 JP 6169494 B2 JP6169494 B2 JP 6169494B2 JP 2013552568 A JP2013552568 A JP 2013552568A JP 2013552568 A JP2013552568 A JP 2013552568A JP 6169494 B2 JP6169494 B2 JP 6169494B2
Authority
JP
Japan
Prior art keywords
mva
influenza
hlha
recombinant
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013552568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506785A (ja
JP2014506785A5 (enExample
Inventor
ファルコ−ギュンター ファルクナー，
ファルコ−ギュンター ファルクナー，
ビルギット シェーファー，
ビルギット シェーファー，
アネット ヘッセル，
アネット ヘッセル，
ペー． ノエル バレット，
ペー． ノエル バレット，
トーマス エール． クライル，
トーマス エール． クライル，
ハルトムート エールリッヒ，
ハルトムート エールリッヒ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ology Bioservices Inc
Original Assignee
Nanotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanotherapeutics Inc filed Critical Nanotherapeutics Inc
Publication of JP2014506785A publication Critical patent/JP2014506785A/ja
Publication of JP2014506785A5 publication Critical patent/JP2014506785A5/ja
Application granted granted Critical
Publication of JP6169494B2 publication Critical patent/JP6169494B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013552568A 2011-01-31 2012-01-30 インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法 Active JP6169494B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438024P 2011-01-31 2011-01-31
US61/438,024 2011-01-31
PCT/US2012/023085 WO2012106231A2 (en) 2011-01-31 2012-01-30 Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017126499A Division JP6461244B2 (ja) 2011-01-31 2017-06-28 インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法

Publications (3)

Publication Number Publication Date
JP2014506785A JP2014506785A (ja) 2014-03-20
JP2014506785A5 JP2014506785A5 (enExample) 2015-03-19
JP6169494B2 true JP6169494B2 (ja) 2017-07-26

Family

ID=45561167

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013552568A Active JP6169494B2 (ja) 2011-01-31 2012-01-30 インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法
JP2017126499A Active JP6461244B2 (ja) 2011-01-31 2017-06-28 インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017126499A Active JP6461244B2 (ja) 2011-01-31 2017-06-28 インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法

Country Status (6)

Country Link
US (2) US9463237B2 (enExample)
EP (1) EP2670430B1 (enExample)
JP (2) JP6169494B2 (enExample)
CN (1) CN103458922B (enExample)
AU (2) AU2012212463B2 (enExample)
WO (1) WO2012106231A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2670430B1 (en) * 2011-01-31 2015-04-01 Baxter International Inc Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses
US10434166B2 (en) * 2013-03-15 2019-10-08 University Of Maryland, College Park Methods and compositions for in vivo immune stimulation and antigen production
US10286062B2 (en) 2013-07-09 2019-05-14 Texas Tech University System Universal influenza vaccine
CA3003103A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
PL3402802T3 (pl) * 2016-01-08 2023-06-05 Geovax, Inc. Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym
US10370416B2 (en) * 2016-03-01 2019-08-06 Texas Tech University System Dual purpose universal influenza vaccine confers protective immunity against anthrax
KR102731582B1 (ko) 2016-06-03 2024-11-15 사노피 파스퇴르 인코포레이티드 조작된 인플루엔자 헤마글루티닌 폴리펩티드의 변형
CN107841513B (zh) * 2016-09-18 2023-04-14 中国科学院上海巴斯德研究所 基于M2e表位的广谱型流感疫苗
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
JP7382634B2 (ja) * 2017-12-21 2023-11-17 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
CN109096376A (zh) * 2018-09-20 2018-12-28 扬州大学 流感病毒ha多肽、klh偶联多肽及多克隆抗体的制备方法
CN113004422B (zh) * 2021-03-04 2023-01-20 辽宁成大生物股份有限公司 一种融合蛋白、含其的疫苗及其应用
WO2023019274A1 (en) * 2021-08-13 2023-02-16 Purdue Research Foundation Methods and compositions for vaccination against heterosubtypic influenza viruses using an adenoviral vector leading to enhanced t cell response through autophagy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
AT393277B (de) 1990-01-04 1991-09-25 Immuno Ag Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen
MX2008009929A (es) * 2006-02-02 2008-10-01 Globeimmune Inc Vacuna a base de levadura para inducir una respuesta inmune.
EP1820511A1 (en) * 2006-02-20 2007-08-22 Prolmmune Limited MHC binding peptides and their uses
CA2673994A1 (en) * 2006-12-29 2008-07-24 Institut Pasteur Of Shanghai Lentivirus pseudotyped with influenza hemagglutinin and methods of use
EP2134361A4 (en) * 2007-03-26 2010-09-22 Univ Massachusetts Medical Compositions and methods for increasing immunogenicity of glycoprotein vaccines
US20110177122A1 (en) * 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
US7998488B2 (en) 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
EP2413962A1 (en) * 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
CA2762044A1 (en) 2009-05-18 2010-11-25 Panacea Biotec Ltd Universal influenza vaccine based on recombinant modified vaccinia ankara virus (mva)
EP2670430B1 (en) 2011-01-31 2015-04-01 Baxter International Inc Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses

Also Published As

Publication number Publication date
WO2012106231A3 (en) 2012-09-20
WO2012106231A2 (en) 2012-08-09
AU2016235002B2 (en) 2018-08-09
EP2670430B1 (en) 2015-04-01
US10329583B2 (en) 2019-06-25
US9463237B2 (en) 2016-10-11
EP2670430A2 (en) 2013-12-11
JP2017221195A (ja) 2017-12-21
US20170121735A1 (en) 2017-05-04
JP6461244B2 (ja) 2019-01-30
CN103458922B (zh) 2017-10-03
AU2012212463B2 (en) 2016-07-07
CN103458922A (zh) 2013-12-18
US20140050759A1 (en) 2014-02-20
JP2014506785A (ja) 2014-03-20
AU2012212463A1 (en) 2013-05-02
AU2016235002A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
JP6461244B2 (ja) インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法
Kumar et al. Novel platforms for the development of a universal influenza vaccine
ES2929942T3 (es) Vacunas contra el virus de la gripe y sus usos
ES2953393T3 (es) Vacunas contra el virus de la influenza y sus usos
US9849172B2 (en) Influenza virus vaccines and uses thereof
Kerstetter et al. Adenoviral vectors as vaccines for emerging avian influenza viruses
US20110159031A1 (en) Vaccine to Influenza A Virus
CN101636177A (zh) 用于禽流感的基于重组改良型痘苗病毒安卡拉(mva)的疫苗
JP2012527232A (ja) 遺伝子組換え改変ワクシニアアンカラウイルス（ｍｖａ）ベースのインフルエンザ万能ワクチン
Pandey et al. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses
CN108348595A (zh) 活重组麻疹-m2病毒-其在诱发针对流感病毒的免疫力中的应用
Girard et al. Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24–26 January 2013
Stropkovská et al. Trends in development of the influenza vaccine with broader cross-protection
Sayedahmed Adenovirus Vector-based Vaccine Approach for Emerging Influenza Viruses
Deal Conserved epitopes in Plasmodium falciparum and influenza A virus as targets for virus-vectored immunization
Kamlangdee Broad Influenza Vaccine Using a Mosaic Hemagglutinin
HK1216392B (en) Influenza virus vaccines and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161214

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170530

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170628

R150 Certificate of patent or registration of utility model

Ref document number: 6169494

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250